A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses
- 1 July 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (10) , 1155-1161
- https://doi.org/10.1097/00002030-199810000-00007
Abstract
Objectives: To illustrate a simple approach to adjusting for bias due to drop-outs (i.e., attrition bias) when evaluating the effect of a certain therapy in HIV clinical trials using the mean change in plasma viral load. To evaluate its validity and to compare its performance with that of another simple method for handling dropouts: the last observation carried forward (LOCF) method. Design: Data from a notional treated group of 100 patients followed up to 52 weeks were generated. Attrition bias was introduced by mimicking selective patient dropout (i.e., more likely in patients doing badly). Methods: The difference between the true mean change in HIV RNA levels at 52 weeks and the observed mean change because of drop-outs was calculated (attrition bias). The reduction in bias obtained by using the proposed approach was then calculated and compared with that obtained by using the LOCF method. To assess the performance of the methods over the entire follow-up, the mean areas under the curves were considered. Results: Our method reduced the bias by a clinically relevant amount in a variety of different settings. In most of our simulations, bias was reduced by a larger amount than that obtainable from using the LOCF method. Conclusions: The current situation is that results from trials in HIV infection are invariably presented with no associated attempt to quantify the attrition bias present. Attrition-adjusted plots of mean change in HIV RNA should, we believe, be presented alongside usual plots as a form of sensitivity analysis.Keywords
This publication has 16 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV InfectionAnnals of Internal Medicine, 1996
- Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 InfectionAnnals of Internal Medicine, 1996
- Impact of Missing Data Due to Dropouts on Estimates of the Treatment Effect in a Randomized Trial of Antiretroviral Therapy for HIV-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV DiseaseAnnals of Internal Medicine, 1995
- Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving ZidovudineAnnals of Internal Medicine, 1994